Stock Events

Bionomics 

€0.77
0
+€0+0% Friday 07:20

Statistics

Day High
0.77
Day Low
0.77
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
8.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

21FebExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-97.2
-64.8
-32.4
-0
Expected EPS
-0.6343
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B1N0.F. It's not an investment recommendation.

About

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Show more...
CEO
Dr. Spyridon Papapetropoulos M.D., Ph.D.
Country
US
ISIN
US09063M2052
WKN
000A3C9JV

Listings